NASDAQ · ALRN
Healthcare · Biotechnology
$2.11
Up+$0.18 (+9.33%)
Updated Sep 16, 2026, 5:22 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ALRN does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ALRN.
ALRN research
Company profile and research snapshot.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 18, 2024 | Ladenburg Thalmann | Buy | — |
| Dec 1, 2023 | Ladenburg Thalmann | Buy | — |
| Jun 30, 2022 | HC Wainwright & Co. | Buy | — |
| Jun 29, 2022 | William Blair | Market Perform | — |
| Jun 5, 2020 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · May 15, 2024
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated
Zacks Investment Research · May 7, 2024
The heavy selling pressure might have exhausted for Aileron Therapeutics (ALRN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
GlobeNewswire Inc. · May 6, 2024
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
GlobeNewswire Inc. · May 3, 2024
Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALRN.
No results
No recent SID articles mention ALRN.
